|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eptifibatide#Adult Indications and Dosage]] |
| {{Eptifibatide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| ===Acute Coronary Syndrome (ACS)===
| |
| | |
| INTEGRILIN is indicated to decrease the rate of a combined endpoint of death or new [[myocardial infarction]] ([[MI]]) in patients with [[ACS]] ([[unstable angina]] [UA]/non-ST-elevation [[myocardial infarction]] [[[NSTEMI]]]), including patients who are to be managed medically and those undergoing [[percutaneous coronary intervention]] ([[PCI]]).
| |
| | |
| ===Percutaneous Coronary Intervention (PCI)===
| |
| | |
| INTEGRILIN is indicated to decrease the rate of a combined endpoint of death, new [[MI]], or need for urgent intervention in patients undergoing [[PCI]], including those undergoing intracoronary stenting [see Clinical Studies (14.1, 14.2)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ad82e30-50d8-450c-8a2a-b4b507ed1ce2 | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |